Drug profile · INN
tapentadol
PALEXIA SR
tapentadol (PALEXIA SR) is a norepinephrine transporter inhibitor. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — tapentadol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
tapentadol (PALEXIA SR) is a norepinephrine transporter inhibitor. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Frequently asked questions
What is tapentadol?
tapentadol (PALEXIA SR) is a norepinephrine transporter inhibitor. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tapentadol?
PALEXIA SR is a marketed brand name for tapentadol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tapentadol?
tapentadol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.